---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-213380"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:09:37.387275+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q1 2026 net loss narrows to $17.9M; evorpacept data shows durable responses

## Summary
- GAAP net loss of $17.9M ($0.17/sh) vs $30.8M ($0.58/sh) YoY; R&D expenses down to $13.6M.
- Cash $169.1M at March 31, 2026; expects to fund operations through first half of 2028.
- Phase 1b/2 evorpacept + zanidatamab data: 60% cORR in ccHER2+ patients; all 5 with high CD47 responded (mPFS 22.1 months).
- Phase 2 ASPEN-09-Breast topline data in mid-2027; Phase 1 ALX2004 safety data in 2H 2026.
- Appointed Jeff Knight as Chief Development and Operating Officer in April 2026.

## SEC filing metadata
- accession: 0001193125-26-213380
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312526213380/0001193125-26-213380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312526213380/alxo-20260508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-213380
- JSON: https://secwatch.observer/filing/0001193125-26-213380.json
- Plain text: https://secwatch.observer/filing/0001193125-26-213380.txt

## Source-grounded claims
- claim_id: bbbbac99014e2ab2c5f367cd440b3cb7f40dee92
  claim: ALX ONCOLOGY HOLDINGS INC reported financial results for the first quarter ended March 31, 2026.
  evidence_excerpt: On May 8, 2026, ALX Oncology Holdings Inc. (the “Company”), issued a press release announcing its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000119312526213380/0001193125-26-213380-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.